FTH News
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026
Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 6, 2026 at 10:00 AM ET featuring Marcus...
Business Wire
What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now?
Does Faeth Therapeutics, Inc. (FTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
Faeth Therapeutics to Participate in Upcoming September Investor Conferences
Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that management will participate in the following upcoming investor conferences:Wells Fargo 21st Annual Healthcare...
Business Wire
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeths Board of Directors granted three new employees options to purchase an aggregate of 94,000 shares of the Companys common stock in connection with their employment (collectively, the Option Awards). The...
Business Wire
Wall Street Analysts Predict a 72.22% Upside in Faeth Therapeutics, Inc. (FTH): Here's What You Should Know
The mean of analysts' price targets for Faeth Therapeutics, Inc. (FTH) points to a 72.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer
Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of sapanisertib and...
Business Wire
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments
Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced the appointments of Deepak Tiwari as Senior Vice President, Technical Operations, and Matt Biegler as Senior Vice President, Investor Relations, as the company prepares for upcoming PIKTOR clinical milestones. Tiwari will lead Faeths technical...
Business Wire
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeths Board of Directors granted two new employees options to purchase an aggregate of 11,000 shares of the Companys common stock in connection with their employment (collectively, the Option Awards). The...
Business Wire
Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference
Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, will present translational data and pharmacokinetic/pharmacodynamic (PK/PD) analysis for PIKTOR, its oral combination of serabelisib...
Business Wire
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates
Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, today announced financial results for the quarter ended June 30, 2026, and highlighted recent corporate accomplishments and 2026...
Business Wire